Description

Sodium Cromoglicate inhibits the degranulation of sensitized mast cells which occurs after exposure to specific antigens. Sodium Cromoglicate acts by inhibiting the release of histamine and various membrane derived mediators of inflammation from mast cells. Sodium Cromoglicate has no vasoconstrictor or antihistaminic activity.

Ophthalmic use: Prevention of acute allergic conjunctivitis, seasonal conjunctivitis, vernal kerato conjunctivitis Nasal use: It is also used for the symptomatic prevention & treatment of seasonal or perennial allergic rhinitis. Prophylactic treatment for seasonal allergic rhinitis should begin 2 to 3 weeks before exposure to the allergen and should continue throughout the season.

This drop is contraindicated in patient with hypersensitivity to Sodium Cromoglicate .

Transient stinging and burning may occur after instillation of this drops. Other symptoms of local irritation have been reported rarely.

Sodium Cromoglicate should be used with caution during pregnancy and only if the expected benefit to the mother is greater than any possible risk to the fetus. There are no known harmful effects when this medicine is used by breastfeeding mothers.

As this drop contains benzalkonium chloride, patients should not wear contact lenses during treatment with this drop.

Overdose is unlikely. In the event of accidental ingestion, symptomatic treatment is recommended.

Mast Cell Stabiliser, Ophthalmic Non-Steroid drugs